PBLA
NASDAQPanbela Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- SECPanbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECPanbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECPanbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form S-8 filed by Panbela Therapeutics Inc.S-8 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- INSIDERSEC Form 4 filed by Large owner Nant Capital, Llc4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECPanbela Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Financial Statements and Exhibits8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 424B3 filed by Panbela Therapeutics Inc.424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECSEC Form 10-Q filed by Panbela Therapeutics Inc.10-Q - Panbela Therapeutics, Inc. (0001029125) (Filer)
- SECPanbela Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
- PRPanbela Provides Business Update and Reports Q3 2024 Financial ResultsMINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,
- PRPanbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.
- 13D/GSEC Form SC 13D filed by Panbela Therapeutics Inc.SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)
PBLA FAQ
6 questionsWhat does Panbela Therapeutics Inc. do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in...Where does PBLA stock trade?
Panbela Therapeutics Inc. (PBLA) is listed on NASDAQ.What sector and industry is PBLA in?
Panbela Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PBLA?
Panbela Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2021-06-28. Recent price targets cluster around $1000.00.What companies are similar to PBLA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PBLA side-by-side with any of them on Quantisnow.How can I track PBLA on Quantisnow?
Quantisnow aggregates Panbela Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PBLA to receive live email and push alerts on every new disclosure.